ポンペ病治療の世界市場2016-2020...市場調査レポートについてご紹介

Table of Contents
PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Disease overview
• Understanding the disease
• Symptoms
• Diagnosis
• Etiology and pathogenesis
• Biochemical pathway
• Epidemiology
• Management
• Economic burden

PART 06: Market landscape
• Market overview
• Five forces analysis

PART 07: Market segmentation by type of Pompe disease

PART 08: Geographical segmentation
• Pompe disease treatment market in EMEA
• Pompe disease treatment market in Americas
• Pompe disease treatment market in US
• Pompe disease treatment market in APAC

PART 09: Market drivers
• Special regulatory drug designations for orphan drugs
• Reimbursement policies for treatment
• Designated under ICD-10 code
• Shorter development timelines

PART 10: Impact of drivers

PART 11: Market challenges
• Limited patient population
• Weak pipeline
• Lack of long-term commitment

PART 12: Impact of drivers and challenges

PART 13: Market trends
• Focus on gene therapy
• Emergence of immunotherapy for Pompe disease
• Growing public awareness

PART 14: Vendor landscape
• Competitive scenario
• Other prominent vendors

PART 15: Key vendor analysis
• Amicus Therapeutics
• Audentes Therapeutics
• Sanofi Genzyme

PART 16: Appendix
• List of abbreviations

PART 17: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Approved drugs for Pompe disease
Exhibit 03: Snapshot of Pompe disease
Exhibit 04: Signs and symptoms of Pompe disease
Exhibit 05: Differential diagnosis of Pompe diseases in infants
Exhibit 06: Differential diagnosis of Pompe diseases in adults and children
Exhibit 07: Biochemical pathway of Pompe disease
Exhibit 08: Approaches used in treating Pompe disease
Exhibit 09: Snapshot of global Pompe disease treatment market 2015
Exhibit 10: Market overview of global Pompe disease treatment market
Exhibit 11: Opportunity analysis in developed and emerging markets
Exhibit 12: Global Pompe disease treatment market 2015-2020 ($ millions)
Exhibit 13: Five forces analysis
Exhibit 14: Market segmentation by type of Pompe disease
Exhibit 15: Snapshot of global Pompe disease treatment market by geography
Exhibit 16: Global Pompe disease treatment market segmentation by geography 2015-2020 ($ millions)
Exhibit 17: Overview of Pompe disease treatment market in EMEA
Exhibit 18: Prevalence rates of Pompe disease (per 100,000) in EMEA 2015
Exhibit 19: Incentives provided for orphan drugs by EU regulation
Exhibit 20: Pompe disease treatment market in EMEA 2015-2020 ($ millions)
Exhibit 21: Overview of Pompe disease treatment market in Americas
Exhibit 22: Prevalence rates of Pompe disease (one in 100,000) in Americas 2015
Exhibit 23: Orphan drug development and regulatory challenges
Exhibit 24: Pompe disease treatment market in Americas 2015-2020 ($ millions)
Exhibit 25: Incentives provided for orphan drugs by US regulation
Exhibit 26: Pompe disease treatment market in US 2015-2020 ($ millions)
Exhibit 27: Overview of Pompe disease treatment market in APAC
Exhibit 28: Prevalence rates of Pompe disease (one in 100,000) in APAC
Exhibit 29: Incentives provided for orphan drugs by Japanese regulation
Exhibit 30: Incentives provided for orphan drugs by Australian regulation
Exhibit 31: Pompe disease treatment market in APAC 2015-2020 ($ millions)
Exhibit 32: US FDA filed to approved time: Orphan drugs versus non-orphan drugs (median time)
Exhibit 33: Impact of drivers
Exhibit 34: Pipeline for Pompe disease treatment 2016
Exhibit 35: Pipeline molecules being developed for the treatment of Pompe disease
Exhibit 36: Pompe disease drugs discontinued from development
Exhibit 37: Impact of drivers and challenges
Exhibit 38: Competitive structure analysis of global Pompe disease treatment market 2015
Exhibit 39: Region-wise combined sales of Myozyme and Lumizyme 2013-2015 ($ millions)
Exhibit 40: Amicus Therapeutics: Key highlights
Exhibit 41: Amicus Therapeutics: Strength assessment
Exhibit 42: Amicus Therapeutics: Strategy assessment
Exhibit 43: Amicus Therapeutics: Opportunity assessment
Exhibit 44: Audentes Therapeutics: Profile
Exhibit 45: Audentes Therapeutics: Strength assessment
Exhibit 46: Audentes Therapeutics: Strategy assessment
Exhibit 47: Audentes Therapeutics: Opportunity assessment
Exhibit 48: Sanofi Genzyme: Key highlights
Exhibit 49: Sanofi Genzyme: Strength assessment
Exhibit 50: Sanofi Genzyme: Strategy assessment
Exhibit 51: Sanofi Genzyme: Opportunity assessment